Gossamer Bio Plans FDA Talks After Narrow Miss In Key Pivotal Study, Stock Sinks

Gossamer Bio Inc. (NASDAQ:GOSS) dropped during early trading on Monday after the company shared topline results from the Phase 3 PROSERA study evaluating seralutinib in pulmonary arterial hypertension.PAH is defined by high blood pressure in the lung arteries due to narrowed, damaged, or destroyed vessels, forcing the heart’s right side to overwork and potentially fail.Disappointing Trial DataAt Week 24, patients receiving seralutinib showed a median change of +28.2 meters in the Six-Minute Walk Distance (6 ...